FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio

FDA approved Merck’s LIPFENDRA (enlicitide) to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct therapy. This regulatory milestone expands Merck’s cardiovascular franchise and supports a positive near-term outlook given the approved indication breadth.

Analysis

FDA approved Merck’s LIPFENDRA (enlicitide) to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct therapy. This regulatory milestone expands Merck’s cardiovascular franchise and supports a positive near-term outlook given the approved indication breadth.